Replies to post #30911 on Anavex Life Sciences Corp (AVXL)

[JB3729]

Too much pre-presentation info. Just like the original presentation title.

[shoeman6]

"They are presenting Full Part A data at the Conf and only prelim Part B. The abstract including info re: Part B would not be proper, thus the change."

[shoeman6]

Also, the sentence was incorrect in context. Read:
"The primary outcome of the study is safety, and ANAVEX 2-73
was well tolerated. In the secondary outcome endpoints preliminary
analysis of data from subjects to date shows an average improvement
of the MMSE score at week 12 in PART B (week 17 from baseline). "

They go from talking about Part A to Part B and confuse the two in the first abstract. A decision was made to stick to the context of Part A. The old sentence made it seem like the secondary outcome endpoints of Part A were being justified by results of the Part B study. See how that would be confusing or even incorrect?